Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21



51039 items
9:46 PM, Jun 20, 2018  |  BC Extra | Financial News

Five biopharmas price IPOs ahead of Thursday trading

Five biopharmas priced IPOs late Wednesday, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated, including one -- cell therapy company Avrobio Inc....
4:00 PM, Jun 20, 2018  |  BC Extra | Company News

Gawande to head Amazon-Berkshire-Chase healthcare company Inc. (NASDAQ:AMZN), Berkshire Hathaway Inc. (NYSE:BRK.A; NYSE:BRK.B) and JPMorgan Chase & Co. (NYSE:JPM) hired Atul Gawande as CEO of their new company focused on U.S. employee healthcare, effective July 9. His experience draws from...
3:54 PM, Jun 20, 2018  |  BC Extra | Preclinical News

Broad ErbB inhibition arrests KRAS mutant cancer

Multi-ErbB inhibitors may provide a treatment option for K-Ras (KRAS)-driven lung cancer where ErbB family member EGFR1-specific therapies have failed, according to two studies published in Science Translational Medicine on Wednesday. The findings suggest a way...
3:45 PM, Jun 20, 2018  |  BC Extra | Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief Accounting...
3:40 PM, Jun 20, 2018  |  BC Extra | Company News

Roche, Tesaro decline to comment on potential bid

Roche (SIX:ROG; OTCQX:RHHBY) and Tesaro Inc. (NASDAQ:TSRO) declined to comment on an Intereconomía report that said Roche is working with Citibank on a bid to acquire Tesaro. Intereconomía cited sources familiar with the matter. This month,...
3:18 PM, Jun 20, 2018  |  BC Extra | Preclinical News

TRPV4 could be new target for brain edema

University of Tokyo researchers and colleagues found inhibiting transient receptor potential vanilloid 4 (TRPV4; VRL2) could help treat brain edema caused by traumatic brain injury or stroke, according to a paper published in The Journal...
2:18 PM, Jun 20, 2018  |  BC Extra | Politics & Policy

Senate rejects clawback attempt

The Senate rejected a bill on Wednesday that would have rescinded more than $7 billion previously approved for the Children’s Health Insurance Program (CHIP). The original legislation proposed by the Trump administration, called the Spending...
1:13 PM, Jun 20, 2018  |  BC Extra | Financial News

ObsEva raises $73M on heels of linzagolix data

ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright. The price is...
1:02 PM, Jun 20, 2018  |  BC Extra | Company News

TG, Novimmune developing CD47/CD19 bispecific

TG Therapeutics Inc. (NASDAQ:TGTX) partnered with Novimmune S.A. (Plan-les-Ouates, Switzerland) to develop Novimmune’s TG-1801 (formerly NI-1701). The companies plan to begin clinical testing of the candidate this year or early next year, with a focus...
12:50 PM, Jun 20, 2018  |  BC Extra | Company News

FDA panel to review Paratek antibiotic

FDA's Antimicrobial Drugs Advisory Committee has scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The agency is reviewing oral and IV versions of the amniomethylcycline antibioitic to treat...